LudwigH., FritzE., KotzmannH.: Erythropoietin in treatment of anemia associated with multiple myeloma.N Engl J Med1990, 322: 1693–1699.
2.
RizzoD., LichtinA.E., WoolfS.H.: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the ASCO and the ASH.J Clin Oncol2002, 20: 4085–4107 e Blood 2002, 100: 2303-2320.
3.
CookD.L., GuyattG.H., LaupacisA.: Rules of evidence and clinical recommendations on the use of antithrombotic agent.Chest1992, 102(Suppl 4): 305S–311S.
4.
SackettD.L.: Rules of evidence and clinical recommendations on the use of antithrombotic agents.Chest1989, 95: 2S–4S.
5.
RizzoD., SeidenfeldJ., PiperM.: Erythropoietin: a paradigm for the development of practice guidelines.Hematology (Am Soc Hematol Educ Program)2001: 10–30.
6.
SeidenfeldJ., PiperM., FlammC.: Epoetin treatment for anemia of cancer therapy: a systematic review and meta-analysis of controlled clinical trials.J Natl Cancer Inst2001, 93: 1204–1214.
7.
CheungW.K., GoonB.L., GuilfoyleM.C.: Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses of healthy subjects.Clin Pharmacol Ther1998, 64: 412–423.
8.
CheungW., MintonN., GunawardenaK.: Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly.Eur J Clin Pharmacol2001, 57: 411–418.
9.
GabriloveJ.L., CleelandC.S., LivingstoneR.B.: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.J Clin Oncol2001, 19: 2875–2882.
10.
DemetriG.D., KrisM., WadeJ.: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor types: results from a prospective community oncology study: Procrit Study Group.J Clin Oncol 1998,16: 3412–3425.
11.
GlaspyJ., BukowskiR, SteibergD.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group.J Clin Oncol1997, 15: 1218–1234.
12.
Anonymous.A randomized double-blind placebo-controlled study with subcutaneous recombinant human erytropoietin in patients with low-risk myelodysplastic syndromes: Italian Cooperative Study Group for rHuEpo in myelodysplatic syndromes.Br J Haematol1998, 103: 1070–1074.
13.
LittlewoodT.J., Bajettae, NortierJ.W.Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized double-blind, placebo-controlled trial.J Clin Oncol2001, 19: 2865–2874.
14.
OsterborgA., BrandbergY., MolostovaV.: Randomized, double blind, placebo controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies.J Clin Oncol2002, 20: 2486–2494.
15.
CaroJ., SalasM., WardA.: Anemia as an independent prognostic factor for survival in patients with cancer. A systematic, quantitative review.Cancer2001, 91: 2214–2221.
